NSE filing, NSE: PAR. Summary written from the filing by ALFA Finder's alert engine.
Par Drugs & Chemicals Ltd: key numbers
- Share price
- ₹114.96
- Market cap
- ₹141.4 Cr
- Revenue (annual)
- ₹103.7 Cr
- Net profit (annual)
- ₹13.11 Cr
- P/E (TTM)
- 9.8×Sector 46.5×
- Promoter holding
- 73.41%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Par Drugs & Chemicals Ltd
All →Par Drugs & Chemicals Board Meeting Date
Par Drugs and Chemicals Limited will hold a board meeting on October 29, 2026, to consider and approve its half-yearly unaudited financial results.
Par Drugs & Chemicals Management Change
Par Drugs re-appointed its statutory auditor and executive director/CEO. These appointments were approved at the company's 27th Annual General Meeting.
Par Drugs & Chemicals Annual General Meeting
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026. Management reviewed the company's financial performance and business affairs during the session.
Par Drugs & Chemicals Other Announcement
Par Drugs and Chemicals Limited is notifying shareholders about access to the FY 2025-26 Annual Report and 27th AGM notice via web-link.
Par Drugs & Chemicals Management Change
Par Drugs and Chemicals Limited has re-appointed M/s. Siddhpura & Co. as Internal Auditor and M/s. Maulin Shah & Associates as Cost Auditor.
Par Drugs & Chemicals Annual General Meeting
Par Drugs and Chemicals Limited has scheduled its 27th Annual General Meeting for September 26, 2026, in Vadodara to transact scheduled ordinary and special business.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.